DR. ROBERT J BEHRENS MD NPI 1215999800

NPI Details

DR. Robert J Behrens, MD is a medical oncology internal medicine in Des Moines, IA with 28 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Robert J Behrens, MD NPI is 1215999800. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF IOWA, RJ & L CARVER COLLEGE OF MEDICINE
Graduation Year:1997

The provider's business location address is:

1221 PLEASANT ST
STE 100
DES MOINES, IA
ZIP 50309
Phone: (515) 282-2921
Fax: (515) 282-1035

The NPI 1215999800 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg (HCPCS:Q5112)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Ferritin (blood protein) level (HCPCS:82728)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Magnesium level (HCPCS:83735)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 4/6/2006 and was last updated on 2/3/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: